Prognostic role of bone erosion in orbital RMS: a report from the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG)

被引:0
|
作者
Di Carlo, Daniela [1 ,2 ]
Fichera, Giulia [3 ]
Minard-Colin, Veronique [4 ]
Coppadoro, Beatrice [5 ]
Orbach, Daniel [6 ]
Cameron, Alison [7 ,8 ]
Albiac Ramos, Monica [9 ]
Ben Arush, Myriam [10 ]
Merks, Johannes H. M. [11 ,12 ]
Bisogno, Gianni [1 ,2 ]
机构
[1] Univ Hosp Padova, Dept Womens & Childrens Hlth, Padua, Italy
[2] Univ Hosp Padova, Div Pediat Hematol Oncol, Padua, Italy
[3] Univ Hosp Padova, Pediat Radiol Unit, Padua, Italy
[4] Univ Paris Saclay, Inst Natl Sante & Rech Med, Gustave Roussy, INSERM,U1015,Gustave Roussy, Villejuif, France
[5] Padova Univ Hosp, Dept Womens & Childrens Hlth, Div Hematol Oncol, I-35128 Padua, Italy
[6] Pitie Salpetriere PSL Univ, Oncol Ctr Care Innovat & Res Children Adolescents, Soins Innovat Rech Oncol Enfant Adolescent & Adult, Inst Curie, Paris, France
[7] Univ Hosp Bristol & Weston NHS Fdn Trust, FRCR Bristol Haematol & Oncol Ctr, Bristol, England
[8] Weston NHS Fdn Trust, Bristol, England
[9] Hosp Valle De Hebron, Dept Radiat Oncol, Barcelona, Spain
[10] Ruth Rappaport Childrens Hosp, Joan & Sanford Weill Pediat Hematol Oncol & Bone, Haifa, Israel
[11] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[12] Univ Utrecht, Univ Med Ctr Utrecht, Div Imaging & Oncol, Utrecht, Netherlands
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
orbital tumor; parameningeal; bone erosion; pediatric rhabdomyosarcoma; RMS; RHABDOMYOSARCOMA; CHILDREN; ADOLESCENTS; HEAD;
D O I
10.3389/fonc.2024.1497193
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Orbital rhabdomyosarcoma (RMS) is often limited to the orbital cavity and has a favorable prognosis. In some cases, the tumor can erode the orbital bone and behave as a parameningeal RMS (PM-RMS); thus, it is treated more intensively. However, the current protocols do not provide any guidance on how to consider different grades of bone erosion (BE) that can vary widely, hampering a uniform classification and the subsequent treatment assignment. With the aim of clarifying the role of BE as a risk factor, we analyzed patients with orbital RMS included in the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) protocol. Methods: We retrospectively analyzed the radiological reports of 199 patients with orbital RMS (PM or not) and defined three grades of BE: minimal (thinning of the bone), moderate (focal bone lysis), and extensive (complete cortical destruction). Results: BE was present in 55 of the 199 (27.6%) patients, which was classified as minimal in 27, moderate in 7, and extensive in 21. Tumors with extensive BE were more frequently large (>5 cm, p = 0.0008) and invasive (T2, p = 0.001). With a median follow-up of 70.4 months (range = 7.1-167.7), a total of 183 patients are alive, with 5-year event-free survival (EFS) and overall survival (OS) rates of 76% (95%CI = 69.2-81.3) and 92% (95%CI = 86.7-94.8), respectively. Patients without any BE had better OS (95% vs. 81%, p = 0.001), but not EFS. Patients with no/minimal/moderate BE had better EFS and OS compared with patients with extensive BE [EFS of 78.1 (95%CI = 71.1-83.5) vs. 57.1 (95%CI = 33.8-74.9), p = 0.0114, respectively, and OS of 94.0 (95%CI = 89.2-96.8) vs. 71.1 (95%CI = 46.6-85.9), p < 0.0001, respectively]. Events and metastatic relapses (in all cases CNS/meningeal) were more frequent in patients with extensive BE. Conclusions: Only those patients with orbital RMS and extensive BE should be considered as PM and should be treated accordingly.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] ROLE OF BONE EROSION IN ORBITAL RMS. A REPORT FROM EPSSG RMS 2005 PROTOCOL
    Di Carlo, Daniela
    Fichera, Giulia
    Coppadoro, Beatrice
    Minard-Colin, Veronique
    Jenney, Meriel
    Mandeville, Henry
    Merks, Hans
    Bisogno, Gianni
    PEDIATRIC BLOOD & CANCER, 2023, 70
  • [2] Rhabdomyosarcoma with unknown primary tumor site: A report from European pediatric Soft tissue sarcoma Study Group (EpSSG)
    Affinita, Maria Carmen
    Merks, Johannes H. M.
    Chisholm, Julia C.
    Haouy, Stephanie
    Rome, Angelique
    Rabusin, Marco
    Brennan, Bernadette
    Bisogno, Gianni
    PEDIATRIC BLOOD & CANCER, 2022, 69 (12)
  • [3] Revisiting Risk Stratification in Patients with Localized Rhabdomyosarcoma (RMS): A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EPSSG)
    Bisogno, G.
    Jenney, M.
    Gallego, S.
    Bergeron, C.
    Merks, J. H.
    Julia, C.
    Ferrari, A.
    Angelica, Z.
    Martelli, H.
    Kelsey, A.
    Glosli, H.
    Colin, V. Minard
    Ben-Arush, M.
    Zanetti, I.
    De Salvo, G. L.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S49 - S50
  • [4] Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)
    Chisholm, Julia
    Mandeville, Henry
    Adams, Madeleine
    Minard-Collin, Veronique
    Rogers, Timothy
    Kelsey, Anna
    Shipley, Janet
    van Rijn, Rick R.
    de Vries, Isabelle
    van Ewijk, Roelof
    de Keizer, Bart
    Gatz, Susanne A.
    Casanova, Michela
    Hjalgrim, Lisa Lyngsie
    Firth, Charlotte
    Wheatley, Keith
    Kearns, Pamela
    Liu, Wenyu
    Kirkham, Amanda
    Rees, Helen
    Bisogno, Gianni
    Wasti, Ajla
    Wakeling, Sara
    Heenen, Delphine
    Tweddle, Deborah A.
    Merks, Johannes H. M.
    Jenney, Meriel
    CANCERS, 2024, 16 (05)
  • [5] EPITHELIOID HEMANGIOENDOTHELIOMA IN CHILDREN: THE EUROPEAN PEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP (EPSSG) EXPERIENCE
    Orbach, Daniel
    Van Noesel, Max M.
    Brennan, Bernadette
    Casanova, Michela
    Schifflers, Stefan
    Corradini, Nadege
    Alaggio, Rita
    Burrieza, Gabriela
    Schoot, Reineke
    Berlanga, Pablo
    Zanetti, Ilaria
    Hjalgrim, Lisa
    Ramirez, Gema
    Ferrari, Andrea
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S256 - S257
  • [6] RHABDOMYOSARCOMA WITH UNKNOWN PRIMARY TUMOR SITE. A REPORT FROM EUROPEAN PEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP (EPSSG)
    Affinita, Maria Carmen
    Merks, Hans
    Chisholm, Julia
    Haouy, Stephanie
    Rome, Angelique
    Rabusin, Marco
    Brennan, Bernadette
    Bisogno, Gianni
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S248 - S249
  • [7] Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG)
    Casanova, Michela
    Brennan, Bernadette
    Alaggio, Rita
    Kelsey, Anna
    Orbach, Daniel
    van Noesel, Max M.
    Corradini, Nadege
    Minard-Colin, Veronique
    Zanetti, Ilaria
    Bisogno, Gianni
    Gallego, Soledad
    Merks, Johannes H. M.
    De Salvo, Gian Luca
    Ferrari, Andrea
    EUROPEAN JOURNAL OF CANCER, 2020, 127 : 123 - 129
  • [8] Genomic index in pediatric synovial sarcoma (SYNOBIO study): The European Pediatric Soft Tissue Sarcoma Group (EpSSG) experience.
    Orbach, Daniel
    Mosseri, Veronique
    Pissaloux, Daniel
    Brennan, Bernadette
    Ferrari, Andrea
    Chibon, Frederic
    Bisogno, Gianni
    De Salvo, Gian Luca
    Chakiba, Camille
    Corradini, Nadege
    Minard-Colin, Veronique
    Kelsey, Anna
    Ranchere-Vince, Dominique
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas: The Prospective NRSTS 2005 Study by the European Pediatric Soft Tissue Sarcoma Study Group (EPSSG)
    Ferrari, A.
    Van Noesel, M. M.
    Brennan, B.
    Zanetti, I.
    Corradini, N.
    Casanova, M.
    Berlanga, P.
    Merks, J.
    Alaggio, R.
    Schifflers, S.
    Ramirez-Villar, G.
    Giraudo, C.
    Burrieza, G. Guillen
    Safwat, A.
    Bisogno, G.
    De Salvo, G. L.
    Orbach, D.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S55 - S55
  • [10] Metastatic rhabdomyosarcoma with exclusive distant lymph node involvement: A European Pediatric Soft tissue sarcoma Study Group (EpSSG) report
    Mercolini, Federico
    Merks, Johannes H. M.
    Minard-Colin, Veronique
    Cameron, Alison
    van Scheltinga, Scheila E. J. Terwisscha
    Sher, Osnat
    Fichera, Giulia
    Orbach, Daniel
    Glosli, Heidi
    Coppadoro, Beatrice
    Gallego, Soledad
    Chisholm, Julia C.
    Bisogno, Gianni
    PEDIATRIC BLOOD & CANCER, 2023, 70 (03)